Discovery of VU2957 (Valiglurax): An mGlu 4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease

Joseph D. Panarese, Darren W. Engers, Yong Jin Wu, Joanne J. Bronson, John E. Macor, Aspen Chun, Alice L. Rodriguez, Andrew S. Felts, Julie L. Engers, Matthew T. Loch, Kyle A. Emmitte, Arlindo L. Castelhano, Michael J. Kates, Michael A. Nader, Carrie K. Jones, Anna L. Blobaum, P. Jeffrey Conn, Colleen M. Niswender, Corey R. Hopkins, Craig W. Lindsley

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Fingerprint Dive into the research topics of 'Discovery of VU2957 (Valiglurax): An mGlu <sub>4</sub> Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds